Seldin 23, excellent for flap retraction.
Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps.
Langenbeck periosteal elevators, wide, blade width 11/16" (17 mm), length 7 1/2" (191 mm).
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm).
Medicine Products:(Date:5/16/2008)...wswire-USNewswire/- "Huh, what did you,say?" is a ...larly our,children. More than 30 million Americans...ring loss and the numbers are growing at a dramati...ren have some form of hearing,loss. An effort to b...oblem,is what led Kathlyn Maguire, who has profoun...
(Date:5/16/2008)... May 19 at 10:15 a.m. Eastern Time, VANCOUVER, Ma...Corporation (TSX: RBM, OTCBB: RPBIF) today announc...scheduled to present at the Rodman & Renshaw,5th A...9th at 10:15 a.m.,EDT., A live web cast of the pr...site at, http://www.responsebio.com/newsroom_event...
(Date:5/16/2008)...unemployed politicians - and economists, ORLANDO...nearly all,voters place health care at the top of ...ral budgetary crunch means none of the health care... candidates is likely to become,law anytime soon, ...., Jousting with Princeton University Health care...
(Date:5/16/2008)... Huntsworth plc (LSE: HNT), "the Group",a leading...munications,group headquartered in London, release...e Group,s performance in the first quarter 2008 (t...t follows below., 15 May 2008, ...nterim Management Statement, Record ne...
Breaking Medicine News(10 mins):Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4(Date:5/15/2008)...ted amount of research reflects depth and breadth ... develop new treatments for ...ghlight impact of Zometa(R), the leading IV, bisph...stage breast cancer, - Four oral sessions to feat...bitor of mTOR, including first results of RECORD-1...
(Date:5/15/2008)....J., May 15 /- Sanofi-avent...hat findings from the,landmark ATHENA study showed...the treatment of patients with atrial fibrillation...scular hospitalizations or death from any,cause by...eeting the study,primary endpoint. The ATHENA resu...
(Date:5/15/2008)...tzerland, May 15 /- Ergonex Pharma to... Administration (FDA) has,granted orphan drug desi...y,arterial hypertension (PAH). Terguride is curren...trial in Europe., "The FDA,s grant of orphan drug...trengthens our development program by offering reg...
(Date:5/15/2008)..., May 15 /- Novavax, Inc. (...d enrollment in the Phase I/IIa,study of its pande...mately,230 subjects. Favorable interim results fro...e-escalation in 70 healthy adult volunteers, were,...ggested that the vaccine,is well tolerated and imm...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 3Providence Saint Joseph Medical Named LA Countys Third Primary Stroke Center 16369 1Providence Saint Joseph Medical Named LA Countys Third Primary Stroke Center 16369 2Nickelodeon Gives Kids a Platform to Voice Their Opinions on Nick News with Linda Ellerbee 3A Election Issues 08 Premiering Sunday April 13 at 9 3A0 16364 1Nickelodeon Gives Kids a Platform to Voice Their Opinions on Nick News with Linda Ellerbee 3A Election Issues 08 Premiering Sunday April 13 at 9 3A0 16364 2Nickelodeon Gives Kids a Platform to Voice Their Opinions on Nick News with Linda Ellerbee 3A Election Issues 08 Premiering Sunday April 13 at 9 3A0 16364 3Nickelodeon Gives Kids a Platform to Voice Their Opinions on Nick News with Linda Ellerbee 3A Election Issues 08 Premiering Sunday April 13 at 9 3A0 16364 4New research shows neuroprotective effect of lovastatin 16362 1Power of molecular imaging reveals secrets of the heart 2830 1Power of molecular imaging reveals secrets of the heart 2830 2...sh Columbia, March 12, 2007--Inflazyme,Pharmaceuti...2007,the preliminary results of the Phase 2b CAPS... clinical difference between,patients who received...s surprisingly large and consistent across a numbe... by Inflazyme and its,external experts to determin...
...tes second quarter BLA filing for C1-inhibitor,rep...wire-FirstCall/ -- Lev,Pharmaceuticals, Inc. (Lev)... U.S. Phase III trial of C1-esterase inhibitor (C1...dema (HAE). In the,acute study, which is part of t...tary Angioedema Nanofiltration Generation,evaluati...
Other Medicine Technology:Inflazyme Announces Outcome of Review of Phase 2b Asthma Study:,Potential Mitigating Factors Identified which Prevent Clear,Interpretation of Results 2Inflazyme Announces Outcome of Review of Phase 2b Asthma Study:,Potential Mitigating Factors Identified which Prevent Clear,Interpretation of Results 3Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 2Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 3Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 4Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 5